pharma is the sole category represented across all 1 tracked stories. Raj Pruthi is most often covered alongside IB-Stim, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.4 in the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Raj Pruthi
pharma is the sole category represented across all 1 tracked stories. Raj Pruthi is most often covered alongside IB-Stim, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.4 in the same window. Each story carries 3 original sources on average, compared with 2.8 for the broader beat in this window. Raj Pruthi appears in 1 tracked Biotech story from March 20, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Raj Pruthi. Shared-story counts are live from our verified record — not editorial picks.
Relmada Therapeutics reported its Q4 2025 results, highlighting progress in its Phase 3 REL-1017 program for major depressive disorder. The company remains focused on completing enrollment for its pivotal trials while maintaining a strategic cash position to reach key clinical milestones.
Raj Pruthi is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.